Skip to main content
Clinical Trials/NCT00785811
NCT00785811
Terminated
Phase 4

Randomized, Double Blind, Placebo Controlled Study of Parallel Groups to Evaluate the Effect of Chronic Supplementation of L-arginine in the Muscular Performance.

Sanofi1 site in 1 country36 target enrollmentStarted: October 2008Last updated:

Overview

Phase
Phase 4
Status
Terminated
Sponsor
Sanofi
Enrollment
36
Locations
1
Primary Endpoint
Fatigue Resistance Factor (FRF)

Overview

Brief Summary

The primary purpose of this study is to evaluate the effect of oral administration of L-arginine in the muscular fatigue of the quadriceps, expressed in terms of the Fatigue Resistance Factor (FRF). The secondary purpose of this study is to evaluate the effect of oral administration of L-arginine in the muscular force the quadriceps.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
20 Years to 55 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

1

Experimental

L-arginine aspartate (Targifor)

Intervention: L-arginine aspartate (Targifor) (Drug)

2

Placebo Comparator

Placebo

Intervention: Placebo L-arginine aspartate (Targifor) (Drug)

Outcomes

Primary Outcomes

Fatigue Resistance Factor (FRF)

Time Frame: Throughout the study

Secondary Outcomes

  • Maximum force in Newton (N) and fast or explosive force(at time 90% of the maximum isometric force)

Investigators

Sponsor
Sanofi
Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials